BLA 761345 · Pfizer INC
Elrexfio
Elranatamab · Injection
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanCDER novel approval, Aug 14, 2023: To treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy
Last checked: Nov 20, 2026Latest source record: Mar 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Aug 14, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
48
5 Phase 3, 30 recruiting
FAERS reports
1,158
989 serious, 279 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME • Cytokine Release Syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving ELREXFIO. Initiate treatment with ELREXFIO step-up dosing schedule to reduce the risk of CRS. Withhold ELREXFIO until CRS resolves or permanently discontinue based on severity [see Dosage and Administration (2.2 , 2.5 ), Warnings and Precautions (5.1) ] . • Neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), and serious and life-threatening reactions, can occur in patients receiving ELREXFIO. Monitor patients for signs and symptoms of neurologic toxicity, including ICANS, during treatment. Withhold ELREXFIO until the neurologic toxicity resolves or permanently discontinue based on severity [see Dosage and...
What it is approved for
From the label in effect Sep 14, 2026.
ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ELREXFIO is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T‑cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 )
Mechanism: Elranatamab-bcmm is a bispecific B-cell maturation antigen (BCMA)-directed T-cell engaging antibody that binds BCMA on plasma cells, plasmablasts, and multiple myeloma cells and CD3 on T-cells leading to cytolysis of the BCMA-expressing cells. Elranatamab-bcmm activated T-cells, caused proinflammatory cytokine release, and resulted in multiple myeloma cell lysis.
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 10, 2025 Supplement 3 · Efficacy OrphanLetterLabel
- Aug 14, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLetterReviewLabel
1 products under this application
- ELREXFIO · ELRANATAMAB 12MG · SOLUTION, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Elranatamab" as an intervention, any sponsor and status, largest first.
PfizerPfizer (PFE)
NCT05623020 · 1,060 participants (planned) · Start Nov 10, 2022 · Primary completion Oct 18, 2030
Drug: Elranatamab; Daratumumab and 3 more · For: Multiple Myeloma
Sites: Daphne, Alabama; Fairhope, Alabama; Mobile, Alabama · 180 sites in all
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT05020236 · 893 participants (planned) · Start Oct 4, 2021 · Primary completion Feb 26, 2026
Drug: Elranatamab; Daratumumab and 2 more · For: Multiple Myeloma
Sites: Clovis, California; Fresno, California; Fort Collins, Colorado · 237 sites in all
- Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After TransplantPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT05317416 · 854 participants · Start Mar 25, 2022 · Primary completion Aug 4, 2027
Drug: Elranatamab; Lenalidomide and 2 more · For: Multiple Myeloma
Sites: Gilbert, Arizona; Los Angeles, California; Santa Monica, California · 209 sites in all
- Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM PatientsPivotal-lookingRecruiting
Intergroupe Francophone du MyelomeResearch network
NCT06918002 · 824 participants (planned) · Start Jul 9, 2025 · Primary completion May 2036
Drug: Elranatamab; Lenalidomide (Revlimid®) and 3 more · For: Multiple Myeloma, Newly Diagnosed
Sites: Brussels, Belgium; Charleroi, Belgium; Liège, Belgium · 69 sites in all
PfizerPfizer (PFE)
NCT06152575 · 492 participants (planned) · Start Feb 8, 2024 · Primary completion Aug 26, 2026
Drug: Elranatamab; Elotuzumab and 4 more · For: Multiple Myeloma
Sites: Mobile, Alabama; Beverly Hills, California; Clovis, California · 268 sites in all
- BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.Pivotal-lookingNot yet recruiting
Anne Louise Tølbøll SørensenAcademic, hospital or other
NCT07474961 · 400 participants (planned) · Start Mar 2027 · Primary completion Dec 2036
Drug: teclistamab OR talquetamab OR elranatamab OR linvoseltamab; BTK inhibitors (ibrutinib and zanubrutinib) · For: Waldenstrom Macroglobulinaemia; Multiple Myeloma
Sites: Copenhagen, Denmark; Aalborg, Denmark; Aarhus, Denmark · 5 sites in all
CellCentric Ltd.Industry
NCT04068597 · 250 participants (planned) · Start Aug 9, 2019 · Primary completion Mar 31, 2027
Drug: CCS1477; Pomalidomide and 9 more · For: Haematological Malignancy; Acute Myeloid Leukemia; Non Hodgkin Lymphoma and 3 more
Sites: Atlanta, Georgia; Indianapolis, Indiana; Bethesda, Maryland · 39 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06106945 · 226 participants (planned) · Start Dec 5, 2023 · Primary completion Jan 24, 2028
Drug: AZD0305; Elranatamab and 2 more · For: Multiple Myeloma
Sites: Duarte, California; Irvine, California; Atlanta, Georgia · 46 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- cytokine release syndrome207
- death115
- malignant neoplasm progression87
- pyrexia82
- immune effector cell-associated neurotoxicity syndrome60
- pneumonia59
- fatigue58
- cytomegalovirus infection reactivation57
- off label use49
- plasma cell myeloma45
- rash45
- infection44
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 5 |
| 2024 | 190 |
| 2025 | 556 |
| 2026 | 407 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Elrexfio (Elranatamab-Bcmm)
2024 spending
$413K
Beneficiaries
n/a
17 claims
Per beneficiary
n/a
$7,071.55 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $413,065 |
Part B: Elrexfio (Elranatamab-Bcmm) · HCPCS J1323
2024 spending
$33.1M
Beneficiaries
277
2,469 claims
Per beneficiary
$119,494
2024 ASP limit $180.15 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $33,099,870 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
Lesokhin AM, Tomasson MH, Arnulf B, et al. · Nat Med 2023 · Clinical Trial, Phase II, Research Support, N.I.H., Extramural
- Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Bahlis NJ, Costello CL, Raje NS, et al. · Nat Med 2023 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Elranatamab Fixed Dosing: A Safe, Effective, and Convenient Dosing Approach.
Elmeliegy M, Soltantabar P, Hibma J, et al. · Target Oncol 2025 · Clinical Trial, Phase II, Multicenter Study
- Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3.
Mohty M, Bahlis NJ, Nooka AK, et al. · Br J Haematol 2024 · Clinical Trial
- Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3.
Iida S, Ito S, Yokoyama H, et al. · Jpn J Clin Oncol 2024 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison.
Mol I, Hu Y, LeBlanc TW, et al. · J Comp Eff Res 2025 · Clinical Trial, Phase II, Comparative Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.